How prostacyclin improves cardiac output in right heart failure in conjunction with pulmonary hypertension

Am J Respir Crit Care Med. 2007 Apr 15;175(8):846-50. doi: 10.1164/rccm.200611-1615OC. Epub 2007 Feb 1.

Abstract

Rationale: Prostacyclin therapy improves patients with pulmonary arterial hypertension, but whether this is attributable to an improved inotropic state of the right ventricle in addition to a decreased pulmonary arterial pulmonary vascular resistance remains unclear.

Objectives: We measured the effects of prostacyclin on load-independent measurements of right ventricular contractility in a model of load-induced acute right ventricular failure.

Methods and results: Persistent right ventricular failure was induced in dogs by a transient (90 min) pulmonary arterial constriction. After constriction release and stabilization, intravenous prostacyclin (epoprostenol) was given at doses of 6 and 12 ng/kg/minute for 30 minutes. Pulmonary vascular resistance was assessed by pressure-flow relationships and right ventricular afterload by effective pulmonary arterial elastance. Right ventricular contractility was estimated by end-systolic elastance and right ventriculoarterial coupling efficiency by the ratio of these elastances. Transient pulmonary arterial constriction persistently increased pulmonary vascular resistance, increased arterial elastance from 1.00 +/- 0.07 to 2.86 +/- 0.26 mm Hg/ml, decreased end-systolic elastance from 1.11 +/- 0.07 to 0.54 +/- 0.02 mm Hg/ml, decreased the ratio of elastances from 1.14 +/- 0.08 to 0.20 +/- 0.02, and cardiac output from 4.6 +/- 0.1 to 2.3 +/- 0.1 L/min (p < 0.05). Epoprostenol did not affect end-systolic elastance; however, it decreased arterial elastance to 1.84 +/- 0.33 mm Hg/ml, and increased the ratio of elastances to 0.46 +/- 0.17 and cardiac output to 3.4 +/- 0.3 L/min (p < 0.05).

Conclusions: In this model of afterload-induced right ventricular failure, prostacyclin improves right ventriculoarterial coupling and cardiac output because of vasodilating effects.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antihypertensive Agents / pharmacology*
  • Cardiac Output / drug effects*
  • Disease Models, Animal
  • Dogs
  • Epoprostenol / pharmacology*
  • Hypertension, Pulmonary / complications
  • Hypertension, Pulmonary / physiopathology*
  • Myocardial Contraction / drug effects
  • Pulmonary Artery / drug effects
  • Pulmonary Artery / physiopathology
  • Vascular Resistance / drug effects
  • Ventricular Dysfunction, Right / complications
  • Ventricular Dysfunction, Right / physiopathology*

Substances

  • Antihypertensive Agents
  • Epoprostenol